Scholarlink

<p>Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia, oxidative stress, and impaired glucose homeostasis. This study investigates the antidiabetic potential of microencapsulated phenolic-rich fractions from <i>Alhagi maurorum</i> (PRF-AM) as a novel nutritional therapy. Phenolic fractions were extracted and encapsulated using a combination of maltodextrin, modified starch, and whey protein concentrate via spray-drying, yielding uniform spherical microcapsules averaging 497.2&#xa0;nm with 91% encapsulation efficiency. Key phenolics identified included gallic, caffeic, cinnamic, and ellagic acids, known for their antioxidant activity. In an alloxan-induced diabetic mouse model, oral administration of PRF-AM (100&#xa0;mg/kg) for five weeks significantly reduced blood glucose, triglycerides, total cholesterol, and LDL cholesterol while increasing HDL levels. Histopathological evaluation confirmed no adverse effects on liver, pancreas, or spleen tissues. Mechanistically, PRF-AM enhanced antioxidant defense by upregulating catalase and suppressing iNOS expression, alongside significant increases in GLUT2 and GLUT4 mRNA levels, promoting improved glucose transport and insulin sensitivity. These findings suggest that microencapsulated phenolic compounds from <i>A. maurorum</i> offer a safe and effective adjunctive approach for diabetes management, combining metabolic regulation with antioxidant and anti-inflammatory benefits.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Phenolic microencapsulation of Alhagi maurorum: a novel approach to enhancing diabetes nutrition therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月7日

查看全文
  • Atiyeh sadeghi kowsarkhizi,
  • Melika Aghili Attar,
  • Mohammad saleh Mafinezhad,
  • Seyedeh Fatemeh Keshmiri,
  • Faezeh Mohammadi,
  • Seyyedeh Zeinab Mostafavi,
  • Negin Shafaei,
  • Ehsan Oskoueian,
  • Ehsan Karimi

摘要

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia, oxidative stress, and impaired glucose homeostasis. This study investigates the antidiabetic potential of microencapsulated phenolic-rich fractions from Alhagi maurorum (PRF-AM) as a novel nutritional therapy. Phenolic fractions were extracted and encapsulated using a combination of maltodextrin, modified starch, and whey protein concentrate via spray-drying, yielding uniform spherical microcapsules averaging 497.2 nm with 91% encapsulation efficiency. Key phenolics identified included gallic, caffeic, cinnamic, and ellagic acids, known for their antioxidant activity. In an alloxan-induced diabetic mouse model, oral administration of PRF-AM (100 mg/kg) for five weeks significantly reduced blood glucose, triglycerides, total cholesterol, and LDL cholesterol while increasing HDL levels. Histopathological evaluation confirmed no adverse effects on liver, pancreas, or spleen tissues. Mechanistically, PRF-AM enhanced antioxidant defense by upregulating catalase and suppressing iNOS expression, alongside significant increases in GLUT2 and GLUT4 mRNA levels, promoting improved glucose transport and insulin sensitivity. These findings suggest that microencapsulated phenolic compounds from A. maurorum offer a safe and effective adjunctive approach for diabetes management, combining metabolic regulation with antioxidant and anti-inflammatory benefits.